StocksMedium•29 September 2026•
1 min read
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $420 Million
Key Facts
1Iovance Biotherapeutics raised its full year 2026 total revenue guidance range to $410 to $420 million.
2The update represents a $55 million increase at the midpoint from the prior range of $350 to $370 million.
3The guidance hike is driven by strong U.S. demand for Amtagvi and Proleukin therapies.
Iovance Biotherapeutics raised its full year 2026 total revenue guidance range to $410 to $420 million. The company said in a statement via GlobeNewswire that the update represents a $55 million increase at the midpoint from the prior range of $350 to $370 million.
The guidance hike is driven by strong U.S. demand for Amtagvi and Proleukin therapies, with the company's authorized treatment center network expanding to approximately 100 centers. IOVA closed at $10.99 on September 28, 2026, having reached a day high of $11.17 during that session.